ClinicalTrials.gg
RecruitingNCT07299825Updated May 8, 2026

A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

A Phase 2 interventional study of A166 in Her 2 Positive Breast Cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Sep 2024, registered Dec 2025).
  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
1,215th of 1,519
40 · median 120
Started
2024
with 221 others
Phase 2
493 of 1,928
243 open now
Primary completion
2027-09
later than 718 of 1,063 live
Registered
1,693rd of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 1,215th largest by planned enrollment of the 1,519 interventional ones that give a count, is one of 222 that started in 2024, is one of 493 in phase 2, reaches primary completion later than 718 of the 1,063 other live ones, and was the 1,693rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates

Read the detailed description

This study will evaluate the efficacy of A166 in patients with HER2-positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates.

A166 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.

03

Conditions studied

  • Her 2 Positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient ≥ 18 years and ≤ 75 years when signing the form.
  2. Breast cancer patients by histopathology and/or cytology documented.
  3. In the advanced or stage, having received no more than 5 , one of which must include a ADC with a topoisomerase inhibitor payload.
  4. Patients must have experienced disease progression or intolerance during or after the most recent treatment prior to randomization.
  5. At least one according to 1.1 criteria.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with A166 or any -targeted antibody-drug conjugate (ADC) with a microtubule inhibitor payload.
  2. Known history of severe to other monoclonal antibodies, or allergy to A166 or their components.
  3. Permanent discontinuation of trastuzumab or its biosimilars due to any toxicity in prior treatments.
  4. Presence of severe corneal epithelial disease at baseline; or inability to perform daily activities without contact lenses.
  5. Presence of spinal cord compression or clinically active central nervous system (CNS) .
  6. Other conditions considered by the investigator to make the patient unsuitable for participation in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    A166

    A166 is administered intravenously at a dose of 4.8 mg/kg every 21 (±3) days (q3w).

    Drug: A166

Interventions

  • DrugA166

    intravenous(IV) infusion (Q3W)

06

What researchers measure

Primary outcomes

  1. Objective response rate(ORR)

    ORR is defined as the percentage of patients who achieve complete response(CR) or partial response (PR), as assessed by investigator per RECIST 1.1

    Time frame: Within 24 months of last patient enrolled

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS, 6-month PFS, 12-month PFS.PFS as assessed by investigator according to RECIST v 1.1

    Time frame: Within 24 months of last patient enrolled

  2. Overall survival (OS)

    OS, 1-year survival rate, 1.5-year survival rate, and 2-year survival rate.OS defined as time from inclusion until death

    Time frame: Within 48 months of last patient enrolled

  3. Disease control rate(DCR)

    DCR is defined as the percentage of patients who achieve CR, PR or stable disease (SD), as assessed by investigator per RECIST 1.1

    Time frame: Within 24 months of last patient enrolled

  4. Duration of response(DOR)

    DoR is defined as the time from the date of first documented CR or PR until date of documented disease progression per RECIST 1.1, as assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: Within 24 months of last patient enrolled

  5. Clinical Benefit Rate (CBR)

    CBR is defined as a patient having a best overall response of a complete response (CR), partial response (PR), or stable disease for at least 6 months.

    Time frame: Within 24 months of last patient enrolled

07

Study locations

1 of 1 sites recruiting
  • Henan Provincial Cancer Hospital
    Zhenzhou, Henan 450000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 23, 2025
StartActual
Sep 20, 2024
Primary completionEst.
Sep 20, 2027
CompletionEst.
Dec 31, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07299825
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Sep 20, 2024
Primary completion
Sep 20, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 8, 2026

Study contacts

Min Yan, Professor
Contact
ym200678@126.com
0371-65588404

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab botidotin

Start the discussion